Near-infrared II Theranostic Agents for the Diagnosis and Treatment of Alzheimer's Disease

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2024 Mar 19

PMID 38502215

Authors

Can Zhou

Fantian Zeng

Haijun Yang

Zeying Liang

Guanyu Xu

Xiao Li

Xingdang Liu

Jian Yang

Affiliations

Soon will be listed here.

Abstract

Background: Near-infrared II theranostic agents have gained great momentum in the research field of AD owing to the appealing advantages. Recently, an array of activatable NIR-II fluorescence probes has been developed to specifically monitor pathological targets of AD. Furthermore, various NIR-II-mediated nanomaterials with desirable photothermal and photodynamic properties have demonstrated favorable outcomes in the management of AD.

Methods: We summerized amounts of references and focused on small-molecule probes, nanomaterials, photothermal therapy, and photodynamic therapy based on NIR-II fluorescent imaging for the diagnosis and treatment in AD. In addition, design strategies for NIR-II-triggered theranostics targeting AD are presented, and some prospects are also addressed.

Results: NIR-II theranostic agents including small molecular probes and nanoparticles have received the increasing attention for biomedical applications. Meanwhile, most of the theranostic agents exhibited the promising results in animal studies. To our surprise, the multifunctional nanoplatforms also show a great potential in the diagnosis and treatment of AD.

Conclusions: Although NIR-II theranostic agents showed the great potential in diagnosis and treatment of AD, there are still many challenges: 1) Faborable NIR-II fluorohpores are still lacking; 2) Biocompatibility, bioseurity and dosage of NIR-II theranostic agents should be further revealed; 3) New equipment and software associated with NIR-II imaging system should be explored.

References

Gustavsson A, Norton N, Fast T, Frolich L, Georges J, Holzapfel D . Global estimates on the number of persons across the Alzheimer's disease continuum. Alzheimers Dement. 2022; 19(2):658-670. DOI: 10.1002/alz.12694. View

Poduslo J, Wengenack T, Curran G, Wisniewski T, Sigurdsson E, Macura S . Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis. 2002; 11(2):315-29. DOI: 10.1006/nbdi.2002.0550. View

Zhu L, Ploessl K, Kung H . PET/SPECT imaging agents for neurodegenerative diseases. Chem Soc Rev. 2014; 43(19):6683-91. PMC: 4159420. DOI: 10.1039/c3cs60430f. View

Yang J, Cheng R, Fu H, Yang J, Kumar M, Lu J . Half-curcumin analogues as PET imaging probes for amyloid beta species. Chem Commun (Camb). 2019; 55(25):3630-3633. DOI: 10.1039/c8cc10166c. View

Staderini M, Martin M, Bolognesi M, Menendez J . Imaging of β-amyloid plaques by near infrared fluorescent tracers: a new frontier for chemical neuroscience. Chem Soc Rev. 2015; 44(7):1807-19. DOI: 10.1039/c4cs00337c. View

Yang J, Zeng F, Ge Y, Peng K, Li X, Li Y . Development of Near-Infrared Fluorescent Probes for Use in Alzheimer's Disease Diagnosis. Bioconjug Chem. 2019; 31(1):2-15. DOI: 10.1021/acs.bioconjchem.9b00695. View

Zhou J, Jangili P, Son S, Ji M, Won M, Kim J . Fluorescent Diagnostic Probes in Neurodegenerative Diseases. Adv Mater. 2020; 32(51):e2001945. DOI: 10.1002/adma.202001945. View

Su D, Diao W, Li J, Pan L, Zhang X, Wu X . Strategic Design of Amyloid-β Species Fluorescent Probes for Alzheimer's Disease. ACS Chem Neurosci. 2022; 13(5):540-551. DOI: 10.1021/acschemneuro.1c00810. View

Kahlke T, Umbers K . Bioluminescence. Curr Biol. 2016; 26(8):R313-4. DOI: 10.1016/j.cub.2016.01.007. View

10.

Zhang D, Singhal S, Lee J . Optical Principles of Fluorescence-Guided Brain Tumor Surgery: A Practical Primer for the Neurosurgeon. Neurosurgery. 2018; 85(3):312-324. DOI: 10.1093/neuros/nyy315. View

11.

Weissleder R, Pittet M . Imaging in the era of molecular oncology. Nature. 2008; 452(7187):580-9. PMC: 2708079. DOI: 10.1038/nature06917. View

12.

Wang C, Huang H, Tsay H, Shiao M, Wu W, Cheng Y . Characterization of Aβ aggregation mechanism probed by congo red. J Biomol Struct Dyn. 2012; 30(2):160-9. DOI: 10.1080/07391102.2012.677767. View

13.

Rodriguez-Rodriguez C, Rimola A, Rodriguez-Santiago L, Ugliengo P, Alvarez-Larena A, Gutierrez-de-Teran H . Crystal structure of thioflavin-T and its binding to amyloid fibrils: insights at the molecular level. Chem Commun (Camb). 2010; 46(7):1156-8. DOI: 10.1039/b912396b. View

14.

Biancalana M, Koide S . Molecular mechanism of Thioflavin-T binding to amyloid fibrils. Biochim Biophys Acta. 2010; 1804(7):1405-12. PMC: 2880406. DOI: 10.1016/j.bbapap.2010.04.001. View

15.

Wang Y, Liu T, Zhang E, Luo S, Tan X, Shi C . Preferential accumulation of the near infrared heptamethine dye IR-780 in the mitochondria of drug-resistant lung cancer cells. Biomaterials. 2014; 35(13):4116-24. DOI: 10.1016/j.biomaterials.2014.01.061. View

16.

Yan J, Zhu J, Zhou K, Wang J, Tan H, Xu Z . Neutral merocyanine dyes: for in vivo NIR fluorescence imaging of amyloid-β plaques. Chem Commun (Camb). 2017; 53(71):9910-9913. DOI: 10.1039/c7cc05056a. View

17.

Yang H, Fang S, Tang Y, Wang C, Luo H, Qu L . A hemicyanine derivative for near-infrared imaging of β-amyloid plaques in Alzheimer's disease. Eur J Med Chem. 2019; 179:736-743. DOI: 10.1016/j.ejmech.2019.07.005. View

18.

Loudet A, Burgess K . BODIPY dyes and their derivatives: syntheses and spectroscopic properties. Chem Rev. 2007; 107(11):4891-932. DOI: 10.1021/cr078381n. View

19.

Ojida A, Sakamoto T, Inoue M, Fujishima S, Lippens G, Hamachi I . Fluorescent BODIPY-based Zn(II) complex as a molecular probe for selective detection of neurofibrillary tangles in the brains of Alzheimer's disease patients. J Am Chem Soc. 2009; 131(18):6543-8. DOI: 10.1021/ja9008369. View

20.

Watanabe H, Ono M, Matsumura K, Yoshimura M, Kimura H, Saji H . Molecular imaging of β-amyloid plaques with near-infrared boron dipyrromethane (BODIPY)-based fluorescent probes. Mol Imaging. 2013; 12(5):338-47. View